Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

Simple item page
dc.contributor.authorJones, Paul W
dc.contributor.authorRennard, Stephen I
dc.contributor.authorAgusti, Alvar
dc.contributor.authorChanez, Pascal
dc.contributor.authorMagnussen, Helgo
dc.contributor.authorFabbri, Leonardo
dc.contributor.authorDonohue, James F
dc.contributor.authorBateman, Eric D
dc.contributor.authorGross, Nicholas J
dc.contributor.authorLamarca, Rosa
dc.contributor.authorCaracta, Cynthia
dc.contributor.authorGil, Esther G
dc.date.accessioned2016-06-07T10:53:45Z
dc.date.available2016-06-07T10:53:45Z
dc.date.issued2011-04-26
dc.date.updated2016-06-01T18:16:28Z
dc.description.abstractBackground: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Methods: In two double-blind, 52-week studies, ACCLAIM/COPD I (n = 843) and II (n = 804), patients were randomised to inhaled aclidinium 200 μg or placebo once-daily. Patients were required to have a postbronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio of ≤70% and FEV1 < 0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p < 0.001). More patients had a SGRQ improvement ≥4 units at 52 weeks with aclidinium versus placebo in ACCLAIM/COPD I (48.1% versus 39.5%; p = 0.025) and ACCLAIM/ COPD II (39.0% versus 32.8%; p = 0.074). The time to first exacerbation was significantly delayed by aclidinium in ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p = 0.01), but not ACCLAIM/COPD I (HR 1.0; 95% CI 0.72 to 1.33; p = 0.9). Adverse events were minor in both studies. Conclusion: Aclidinium is effective and well tolerated in patients with moderate to severe COPD.en_ZA
dc.identifier.apacitationJones, P. W., Rennard, S. I., Agusti, A., Chanez, P., Magnussen, H., Fabbri, L., ... Gil, E. G. (2011). Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. <i>Respiratory Research</i>, http://hdl.handle.net/11427/19932en_ZA
dc.identifier.chicagocitationJones, Paul W, Stephen I Rennard, Alvar Agusti, Pascal Chanez, Helgo Magnussen, Leonardo Fabbri, James F Donohue, et al "Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease." <i>Respiratory Research</i> (2011) http://hdl.handle.net/11427/19932en_ZA
dc.identifier.citationJones, P. W., Rennard, S. I., Agusti, A., Chanez, P., Magnussen, H., Fabbri, L., ... & Caracta, C. (2011). Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respiratory research, 12(1), 55.en_ZA
dc.identifier.issn1465-9921en_ZA
dc.identifier.ris TY - Journal Article AU - Jones, Paul W AU - Rennard, Stephen I AU - Agusti, Alvar AU - Chanez, Pascal AU - Magnussen, Helgo AU - Fabbri, Leonardo AU - Donohue, James F AU - Bateman, Eric D AU - Gross, Nicholas J AU - Lamarca, Rosa AU - Caracta, Cynthia AU - Gil, Esther G AB - Background: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Methods: In two double-blind, 52-week studies, ACCLAIM/COPD I (n = 843) and II (n = 804), patients were randomised to inhaled aclidinium 200 μg or placebo once-daily. Patients were required to have a postbronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio of ≤70% and FEV1 < 0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p < 0.001). More patients had a SGRQ improvement ≥4 units at 52 weeks with aclidinium versus placebo in ACCLAIM/COPD I (48.1% versus 39.5%; p = 0.025) and ACCLAIM/ COPD II (39.0% versus 32.8%; p = 0.074). The time to first exacerbation was significantly delayed by aclidinium in ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p = 0.01), but not ACCLAIM/COPD I (HR 1.0; 95% CI 0.72 to 1.33; p = 0.9). Adverse events were minor in both studies. Conclusion: Aclidinium is effective and well tolerated in patients with moderate to severe COPD. DA - 2011-04-26 DB - OpenUCT DO - 10.1186/1465-9921-12-55 DP - University of Cape Town J1 - Respiratory Research LK - https://open.uct.ac.za PB - University of Cape Town PY - 2011 SM - 1465-9921 T1 - Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease TI - Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease UR - http://hdl.handle.net/11427/19932 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/19932
dc.identifier.urihttp://dx.doi.org/10.1186/1465-9921-12-55
dc.identifier.vancouvercitationJones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research. 2011; http://hdl.handle.net/11427/19932.en_ZA
dc.languageengen_ZA
dc.language.rfc3066en
dc.publisherBioMed Centralen_ZA
dc.publisher.departmentDivision of Pulmonologyen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rightsCreative Commons Attribution 4.0 International (CC BY 4.0)*
dc.rights.holderJones et al; licensee BioMed Central Ltd.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_ZA
dc.sourceRespiratory Researchen_ZA
dc.titleEfficacy and safety of once-daily aclidinium in chronic obstructive pulmonary diseaseen_ZA
dc.typeJournal Articleen_ZA
uct.type.filetype
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12931_2010_Article_1080.pdf
Size:
540.58 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.72 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles